Selectivity and therapeutic inhibition of kinases: to be or not to be?
about
Recent advances in understanding psoriasisJakpot! New small molecules in autoimmune and inflammatory diseasesEnabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitorMechanisms of drug resistance in kinases.Peptide substrates for Rho-associated kinase 2 (Rho-kinase 2/ROCK2)A computational approach to finding novel targets for existing drugsSTATs in cancer inflammation and immunity: a leading role for STAT3Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Small-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.Identification of novel signaling components in N,N'-dinitrosopiperazine-mediated metastasis of nasopharyngeal carcinoma by quantitative phosphoproteomics.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approachTofacitinib suppresses antibody responses to protein therapeutics in murine hosts.A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsiesAnti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.Tyrosine kinases in inflammatory dermatologic disease.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionChemical proteomics: terra incognita for novel drug target profiling.Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors.Fragment screening of cyclin G-associated kinase by weak affinity chromatography.Chemical interrogation of the neuronal kinome using a primary cell-based screening assay.STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors.Janus kinase-3 dependent inflammatory responses in allergic asthmaSunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.Lack of association between JAK3 gene polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis.FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphomaIncreased HCMV seroprevalence in patients with hepatocellular carcinoma.Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.Inhibitory Effect of Curcumol on Jak2-STAT Signal Pathway Molecules of Fibroblast-Like Synoviocytes in Patients with Rheumatoid ArthritisMechanisms of Jak/STAT signaling in immunity and diseaseCombined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinomaIL-2 regulates expression of C-MAF in human CD4 T cellsThe use of novel selectivity metrics in kinase research.JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.The dynamics of signaling as a pharmacological target.Navigating the network: signaling cross-talk in hematopoietic cells.Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
P2860
Q26751223-F24A7888-EC54-4D51-A72F-9B4C91020EC8Q27001957-FFCB2A19-7F47-43D2-8196-30552274EC8FQ27673465-C6AB0C59-EBA7-4B30-8E72-E5CD7C9A8444Q27692567-39839582-7FDE-4E4F-833B-5E2949F82DE5Q28476345-2F3CABF8-8B6B-4409-9310-ACD6620FD2F8Q28476770-F02CD21C-A55A-4D64-8D4B-57381DA5756BQ29547203-57444B41-8070-4374-A175-A2C8770ACC63Q30426853-61746CDE-165E-4179-8B74-7A7B8CA66BE4Q33756524-35772C42-FDF9-4375-A22F-5847EB3BFEB0Q33913996-B26ADFE6-A16C-4285-932D-644E5D097068Q33925323-0739C400-34A0-4E1E-AB1F-B695C6A9634EQ33932779-4BF24086-46BD-48AD-99D2-BEF2AAEA281AQ34024820-2850D7D1-5EC2-489D-92E7-D75BF1B3EF2AQ34084020-5108EEE2-FF52-4930-9DA5-69598725A21CQ34166503-34F50BBA-9C57-4162-A157-1EE72539C739Q34169114-7FB38B2F-C36E-4820-9E1F-CD555ED0864DQ34175958-D1EA6386-9C8A-43D3-91DE-66621583D240Q34284580-19F3DF7B-E611-4F33-88F5-6B4D6295AA8AQ34359495-DF5EF549-8F9A-4C2E-9E89-4412A1DA92BDQ34392316-3D5BB720-D6F1-4BBE-8C06-B6E53E87D27CQ34616753-6822A712-041F-44FB-A75F-3DBB03246142Q34936215-4C99E84A-F800-48BF-920D-CFE56E551E6EQ35031161-48A51A04-1258-4732-97F2-32B4CFC4E417Q35033957-0C9C0877-1AA6-47FA-BCA9-CFD4DADC071CQ35080328-DF1B0A10-D837-415A-8D97-8CA2C43CBC4FQ35178124-DD735A4E-8419-452A-B076-DED410348A44Q35346411-12CABC4F-E7D1-49AD-AEE7-628761945D5BQ35574918-F6D08D6C-8864-4AF7-B8E3-8625F6141A2BQ35822851-DD638FBF-A9D5-41CC-A3E5-8A34C72CBA32Q35846015-28924F30-3094-41B3-BDE0-AE1620BF6C6DQ35915068-88660884-FD05-4BCE-93CE-BF720E970068Q35923178-D1349DCC-1AD3-4304-ACA1-21C50F5202F5Q36150570-63775F34-2020-475D-ABD8-9A49DE58D6B4Q36205754-EF14641A-AAE8-4894-B337-280E6C8C48B5Q36240657-344C2EE8-AEF1-4228-97EC-EA1FA0054C94Q36404704-FF56176B-D416-4F37-AD4E-C0E01A1FD876Q37376115-47FAE5C8-0A17-402B-8CC9-94FD2208B041Q37417479-E759D577-A5CE-4FDE-97A4-19FA2B473463Q37521242-2B7C7B86-C531-42A6-B63D-D41B6A31BD9AQ37606284-83556E7D-0658-45C3-B787-01144736CF51
P2860
Selectivity and therapeutic inhibition of kinases: to be or not to be?
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@ast
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@en
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@nl
type
label
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@ast
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@en
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@nl
prefLabel
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@ast
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@en
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@nl
P2093
P2860
P3181
P356
P1433
P1476
Selectivity and therapeutic inhibition of kinases: to be or not to be?
@en
P2093
Arian Laurence
John J O'Shea
Kamran Ghoreschi
P2860
P304
P3181
P356
10.1038/NI.1701
P407
P577
2009-04-01T00:00:00Z